A1ZN34:BVMF
Astrazeneca Plc Bdr
139,90 BRL
0,00%
(0,00) 1D
16 tet, 5:06:00 m.d., GMT-3 · BRL
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për A1ZN34...
Hap
143,33 BRL
I lartë
143,33 BRL
I ulët
138,81 BRL
Kapitalizimi i tregut
259,42 mld
Vëllimi mesatar
892,00
Vëllimi
1,25 mijë
Maksimumi 52-javor
190,40 BRL
Minimumi 52-javor
129,06 BRL
Aksionet në qarkullim
1,55 mld
Numri i punonjësve
96 mijë
Hap
143,33 BRL
I lartë
143,33 BRL
I ulët
138,81 BRL
Kapitalizimi i tregut
259,42 mld
Vëllimi mesatar
892,00
Vëllimi
1,25 mijë
Maksimumi 52-javor
190,40 BRL
Minimumi 52-javor
129,06 BRL
Aksionet në qarkullim
1,55 mld
Numri i punonjësve
96 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Insider Monkey
·
2 ditë më parë
AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?
Traders Union
·
2 ditë më parë
AstraZeneca shares technical analysis: Upward price move confirms strong near-term momentum
The Twelfth Magpie
·
2 ditë më parë
While the market panics about the FTSE 100, Citi just raised its AstraZeneca target to £186
JournalArta
·
2 ditë më parë
AstraZeneca Stock Analysis: Gains 3.24%, Testing Key Resistance
Profili
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
Rreth Astrazeneca Plc Bdr
Drejtori ekzekutivPascal Soriot
Punonjësit96,1 mijë
Themeluar më6 pri 1999
SeliaKembrixh, Cambridgeshire, Mbretëria e Bashkuar
Sektori-
Uebsajtiastrazeneca.com